Dianthus Therapeutics Announces Unregistered Equity Sales
Market News

Dianthus Therapeutics Announces Unregistered Equity Sales

Dianthus Therapeutics (DNTH) has released an update to notify the public and investors about the unregistered sales of equity securities.

The disclosures provided in Item 1.01 are also included in this section as mandated by Form 8-K requirements.

For further insights into DNTH stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyDianthus price target raised to $52 from $48 at Oppenheimer
TipRanks Auto-Generated NewsdeskDianthus Therapeutics Reports Q3 Progress and Financials
TheFlyDianthus reports Q3 EPS (74c), consensus (59c)
Go Ad-Free with Our App